Skip to main content
TipRanks
Go Ultimate75% OFF

MiNK Therapeutics (INKT) Stock Forecast & Price Target

275 Followers
See the Price Targets and Ratings of:

INKT Analyst Ratings

Moderate Buy
2Ratings
2Buy0Hold0Sell
Based on 2 analysts giving stock ratings to MiNK Therapeutics in the past 3 months

INKT Stock 12 Month Forecast

$44.00▲(448.63% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for MiNK Therapeutics in the last 3 months. The average price target is $44.00 with a high forecast of $50.00 and a low forecast of $38.00. The average price target represents a 448.63% change from the last price of $8.02.
Highest Price Target$50.00Average Price Target$44.00Lowest Price Target$38.00

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for INKT
Price TargetArticle
B. Riley Securities$50buy523.44%UpsideReiterated11/12/26
H.C. Wainwright$38buy373.82%UpsideReiterated11/09/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
IMUXImmunic
MDWDMediwound
PTGXProtagonist Therapeutics
KRSAKorsana Biosciences
AXGNAxoGen

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MiNK Therapeutics

3 Months
Mayank Mamtani
Mayank MamtaniB. Riley Securities
Success Rate1/6 ratings generated profit
17%
Average Return
-20.13%

Copying Mayank Mamtani's trades and holding each position for 3 Months would result in 16.67% of your transactions generating a profit, with an average return of -20.13% per trade.

1 Year
Mayank Mamtani
Mayank MamtaniB. Riley Securities
Success Rate0/6 ratings generated profit
0%
Average Return
-34.10%

Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -34.10% per trade.

2 Years
Mayank Mamtani
Mayank MamtaniB. Riley Securities
Success Rate0/6 ratings generated profit
0%
Average Return
-36.08%

Copying Mayank Mamtani's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -36.08% per trade.

INKT Analyst Recommendation Trends

01234Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for INKT
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy11124
Buy00000
Hold00000
Sell00000
Strong Sell00000
total11124

In the current month, INKT has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. INKT average Analyst price target in the past 3 months is 44.00.

INKT Financial Forecast

$-2$-1.5$-1$-0.5$0Q1 2026Q3 2026Q4 2026
High$-0.59
Consensus$-0.61
Low$-0.63

INKT Earnings Forecast

Next quarter’s earnings estimate for INKT is -$0.61 with a range of -$0.63 to -$0.59. The previous quarter’s EPS was -$0.50. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

$-1$62,499.5$125,000$187,500.5$250,001Q1 2026Q3 2026Q4 2026
High$250K
Consensus$125K
Low$0.00

INKT Sales Forecast

Next quarter’s sales forecast for INKT is $125.00K with a range of $0 to $250.00K. The previous quarter’s sales results were $200.00K. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

INKT Stock Forecast FAQ

What is INKT’s average 12-month price target, according to analysts?
Based on analyst ratings, MiNK Therapeutics’s 12-month average price target is $44.00.
What is INKT’s upside potential, based on the analysts’ average price target?
MiNK Therapeutics has 448.63% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is INKT a Buy, Sell or Hold?
MiNK Therapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is MiNK Therapeutics’s price target?
The average price target for MiNK Therapeutics is $44.00. This is based on 2 12-month price targets, issued in the past 3 months. The highest analyst price target is $50.00, the lowest forecast is $38.00. The average price target represents a 448.63% increase from the current price of $8.02.
What do analysts say about MiNK Therapeutics?
MiNK Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Street analysts.
How can I buy shares of INKT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.